Article

Novel brain expression of ClC-1 chloride channels and enrichment of CLCN1 variants in epilepsy

From the Departments of Neurology (T.T.C., T.L.K., A.M.G., J.L.N.), Molecular and Human Genetics (J.L.N.), and Neuroscience (J.L.N.), Baylor College of Medicine, Houston, TX
Neurology (Impact Factor: 8.3). 02/2013; 80(12). DOI: 10.1212/WNL.0b013e31828868e7
Source: PubMed

ABSTRACT OBJECTIVE: To explore the potential contribution of genetic variation in voltage-gated chloride channels to epilepsy, we analyzed CLCN family (CLCN1-7) gene variant profiles in individuals with complex idiopathic epilepsy syndromes and determined the expression of these channels in human and murine brain. METHODS: We used parallel exomic sequencing of 237 ion channel subunit genes to screen individuals with a clinical diagnosis of idiopathic epilepsy and evaluate the distribution of missense variants in CLCN genes in cases and controls. We examined regional expression of CLCN1 in human and mouse brain using reverse transcriptase PCR, in situ hybridization, and Western immunoblotting. RESULTS: We found that in 152 individuals with sporadic epilepsy of unknown origin, 96.7% had at least one missense variant in the CLCN genes compared with 28.2% of 139 controls. Nonsynonymous single nucleotide polymorphisms in the "skeletal" chloride channel gene CLCN1 and in CLCN2, a putative human epilepsy gene, were detected in threefold excess in cases relative to controls. Among these, we report a novel de novo CLCN1 truncation mutation in a patient with pharmacoresistant generalized seizures and a dystonic writer's cramp without evidence of variants in other channel genes linked to epilepsy. Molecular localization revealed the unexpectedly widespread presence of CLCN1 mRNA transcripts and the ClC-1 subunit protein in human and murine brain, previously believed absent in neurons. CONCLUSIONS: Our findings support a possible comorbid contribution of the "skeletal" chloride channel ClC-1 to the regulation of brain excitability and the need for further elucidation of the roles of CLCN genes in neuronal network excitability disorders.

Download full-text

Full-text

Available from: Alica Goldman, Aug 08, 2014
1 Follower
 · 
138 Views
  • Source
    • "Even the observation that the Gly544Arg mutation strongly impaired ClC-4 ion transport does not prove a role of CLCN4 in human epilepsy, especially because Clcn4 À/À mice do not display seizures or any other obvious phenotype (Rickheit et al., 2010). Interestingly, recent work has found an enrichment of missense mutations in CLCN1 and CLCN2, but not of CLCN4 in individuals with complex idiopathic epilepsy syndromes (Chen et al., 2013). However it is important to note that the ClC-1 Cl-channel is predominantly expressed in skeletal muscle (Steinmeyer et al., 1991) and mutations in its gene cause myotonia (Koch et al., 1992; Jentsch, 2008), while previous work claiming a causative role of CLCN2 in epilepsy has been retracted (Haug et al., 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE: The management of epilepsy in children is particularly challenging when seizures are resistant to antiepileptic medications, or undergo many changes in seizure type over time, or have comorbid cognitive, behavioral, or motor deficits. Despite efforts to classify such epilepsies based on clinical and electroencephalographic criteria, many children never receive a definitive etiologic diagnosis. Whole exome sequencing (WES) is proving to be a highly effective method for identifying de novo variants that cause neurologic disorders, especially those associated with abnormal brain development. Herein we explore the utility of WES for identifying candidate causal de novo variants in a cohort of children with heterogeneous sporadic epilepsies without etiologic diagnoses. METHODS: We performed WES (mean coverage approximately 40×) on 10 trios comprised of unaffected parents and a child with sporadic epilepsy characterized by difficult-to-control seizures and some combination of developmental delay, epileptic encephalopathy, autistic features, cognitive impairment, or motor deficits. Sequence processing and variant calling were performed using standard bioinformatics tools. A custom filtering system was used to prioritize de novo variants of possible functional significance for validation by Sanger sequencing. KEY FINDINGS: In 9 of 10 probands, we identified one or more de novo variants predicted to alter protein function, for a total of 15. Four probands had de novo mutations in genes previously shown to harbor heterozygous mutations in patients with severe, early onset epilepsies (two in SCN1A, and one each in CDKL5 and EEF1A2). In three children, the de novo variants were in genes with functional roles that are plausibly relevant to epilepsy (KCNH5, CLCN4, and ARHGEF15). The variant in KCNH5 alters one of the highly conserved arginine residues of the voltage sensor of the encoded voltage-gated potassium channel. In vitro analyses using cell-based assays revealed that the CLCN4 mutation greatly impaired ion transport by the ClC-4 2Cl(-) /H(+) -exchanger and that the mutation in ARHGEF15 reduced GEF exchange activity of the gene product, Ephexin5, by about 50%. Of interest, these seven probands all presented with seizures within the first 6 months of life, and six of these have intractable seizures. SIGNIFICANCE: The finding that 7 of 10 children carried de novo mutations in genes of known or plausible clinical significance to neuronal excitability suggests that WES will be of use for the molecular genetic diagnosis of sporadic epilepsies in children, especially when seizures are of early onset and difficult to control.
    Epilepsia 05/2013; DOI:10.1111/epi.12201 · 4.58 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Chen et al.(1) report 2 novel findings: a truncation mutation in the CLCN1 gene, encoding the chloride channel protein CIC-1, in a patient with myotonic dystrophy and generalized epilepsy; and an excess of variation in CLCN1 in patients with epilepsy compared to controls. They also demonstrate expression of C1C-1 mRNA and protein in human brain autopsy specimens and mouse brain. Mutations in the CLCN1 gene have been long recognized as the cause of dominant (Thomsen-type) and recessive (Becker-type) myotonia but an association with epilepsy has not been reported. Until now it was believed that ClC-1 protein and channels were not expressed in the brain; therefore, the mutation would have no effect on the CNS. The patient reported in this study had generalized epilepsy and generalized seizures, which involve thalamo-cortical circuits. Interestingly, the authors found that ClC-1 mRNA was moderately expressed in the mouse thalamus and cortex. The clinical phenotype, combined with the animal data, strongly suggests a role for ClC-1 in the brain.
    Neurology 02/2013; 80(12). DOI:10.1212/WNL.0b013e3182886a2c · 8.30 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Over the last few decades intensive studies have been carried out on the molecular targets mediating general anesthesia as well as the effects of general anesthetics. The gamma-aminobutyric acid type A receptor (GABAAR) has been indicated as the primary target of general anaesthetics such as propofol, etomidate and isoflurane, and sedating drugs including benzodiazepines and barbiturates. The GABAAR is also involved in drug tolerance and dependence. However, the involvement of other ion channels is possible. Using reverse transcription and quantitative PCR techniques, we systematically investigated changes in the mRNA levels of ion channel genes in response to exposure to midazolam, pentobarbital and ketamine in a freshwater model animal, Daphnia pulex. To retrieve the sequences of Daphnia ion channel genes, Blast searches were performed based on known human or Drosophila ion channel genes. Retrieved sequences were clustered with the maximum-likelihood method. To quantify changes in gene expression after the drug treatments for 4 hours, total RNA was extracted and reverse transcribed into cDNA and then amplified using quantitative PCR. A total of 108 ion channel transcripts were examined, and 19, 11 and 11 of them are affected by midazolam (100 muM), pentobarbital (200 muM) and ketamine (100 muM), respectively, covering a wide variety of ion channel types. There is some degree of overlap with midazolam- and pentobarbital-induced changes in the mRNA expression profiles, but ketamine causes distinct changes in gene expression pattern.In addition, flumazenil (10 muM) eliminates the effect of midazolam on the mRNA expression of the GABAA receptor subunit Rdl, suggesting a direct interaction between midazolam and GABAA receptors. Recent research using high throughput technology suggests that changes in mRNA expression correlate with delayed protein expression. Therefore, the mRNA profile changes in our study may reflect the molecular targets not only in drug actions, but also in chronic drug addiction. Our data also suggest the possibility that hypnotic/anesthetic drugs are capable of altering the functions of the nervous system, as well as those non-nerve tissues with abundant ion channel expressions.
    BMC Anesthesiology 10/2013; 13(1):32. DOI:10.1186/1471-2253-13-32 · 1.33 Impact Factor
Show more